Clinical Trial Update: Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) [Phase 2]

View source ↗

Summary

A Phase 2 randomized evaluation of the AGE breaker alagebrium for diastolic heart failure has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Alagebrium (alagebrium)

Snippet

Sponsor: Synvista Therapeutics, Inc | Conditions: Diastolic Heart Failure | Phase 2 | Status: TERMINATED